Overview

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Status:
Completed
Trial end date:
2020-05-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of IV peramivir compared to a standard 5 day course of oral oseltamivir in the treatment of pediatric subjects with acute uncomplicated influenza.
Phase:
Phase 3
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Treatments:
Oseltamivir
Peramivir